Emmaus Life Sciences posts Q3 2025 results update

Emmaus Life Sciences, Inc. filed a current report to note that it issued a press release on November 14, 2025 announcing its results of operations and financial condition for the three months ended September 30, 2025.

Rhea-AI Filing Summary

Emmaus Life Sciences, Inc. filed a current report to note that it issued a press release on November 14, 2025 announcing its results of operations and financial condition for the three months ended September 30, 2025. The company attached this press release as Exhibit 99.1 and incorporated it by reference. The company also clarified that the earnings information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Emmaus (EMMA) report in its latest SEC filing?

Emmaus Life Sciences, Inc. reported that it issued a press release on November 14, 2025 announcing its results of operations and financial condition for the three months ended September 30, 2025, which is attached as Exhibit 99.1.

Which period do the Emmaus (EMMA) results disclosed on November 14, 2025 cover?

The results announced by Emmaus Life Sciences, Inc. on November 14, 2025 cover its operations and financial condition for the three months ended September 30, 2025.

How is the Emmaus (EMMA) earnings information treated under the Exchange Act?

Emmaus stated that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to Section 18 liabilities of the Exchange Act and is not automatically incorporated by reference into other Securities Act or Exchange Act filings.

Where can investors find the detailed quarterly results for Emmaus (EMMA)?

Detailed quarterly results are contained in the company’s November 14, 2025 press release, which is attached to the report as Exhibit 99.1 and listed in the Index to Exhibits.

What exhibits did Emmaus (EMMA) include with this current report?

Emmaus included Exhibit 99.1, the November 14, 2025 press release, and an exhibit described as the Cover Page Interactive Data File embedded within the Inline XBRL document.

Who signed the November 14, 2025 report for Emmaus (EMMA)?

The report was signed on behalf of Emmaus Life Sciences, Inc. by Willis Lee, who is identified as the company’s Chairman and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 04:21 PM Learn about SEC filing dates

false 0000822370 0000822370 2025-11-14 2025-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

Emmaus Life Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-35527		87-0419387
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

21250 Hawthorne Boulevard, Suite 800, Torrance, CA		90503
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (310) 214-0065

(Former name or former address, if changed, since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class		Trading Symbol		Name of each exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operation and Financial Condition.

On November 14, 2025, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) issued a press release announcing our results of operations and financial condition as of and for the three months ended Sseptember 30, 2025, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated herein by reference.

The information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

See the accompanying Index to Exhibits, which is incorporated herein by reference.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 14, 2025	Emmaus Life Sciences, Inc.
	By:	/s/ WILLIS LEE
		Name:	Willis Lee
		Title:	Chairman and Chief Executive Officer

2

INDEX TO EXHIBITS

Exhibit Number		Description
99.1		November 14, 2025 Press Release
104		Cover Page Interactive Date File (embedded within Inline XBRL document)

3